.png){kind=icon}
.png){kind=icon}
Return
Quality of life endpoints in advanced gastrointestinal cancer trials: Systematic review of inclusion, challenges, and implications (2020–2024)
.png){kind=icon}
PRE
AI
S
B
J
T
R
DOI：10.1016/j.clon.2026.104221.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• Only 60% of phase III GI cancer trials included QoL endpoints (2020–2024). • No trial designated QoL as a primary endpoint despite clinical relevance. • Multi-country trials were ∼7× more likely to include QoL assessment (aOR = 0.15). • QoL inclusion highest in biliary and gastric, lowest in pancreatic cancers. • Findings reveal inequities and call for standardized QoL integration.
Journal
IF:
3
Papers:
4.7K
Citations:
4.7K
Organization
Cited Papers